In response to a question on whether children would be enrolled as volunteers for vaccine trials, Paul said there is a general dictum for trials of vaccines and drugs as per which their safety and efficacy is established in adult before their being tried on children (unless the vaccines are for children only), pregnant women or old age people.
As part of a vastly accelerated logistics operation, doses of various candidate vaccines are already being manufactured, even before the results of final studies have been submitted for approval by regulators.
AstraZeneca also said "reactogenicity" - expected adverse reactions to the virus, which commonly include sore arm or swelling - was lower in older people than younger people.
But should a vaccine become available, many people in Ireland say they will not take it. 19% of those aged between 25 and 34 and 18% of those aged between 18 and 24 said they would not take a Covid-19 vaccine, according to a new poll carried out by Ipsos-MRBI for the IPHA.
The July results showed that the vaccine increased levels of the protective neutralizing antibodies and immune T-cells that target the virus.
"A Covid-19 vaccine will only be deployed once it has been proven to be safe and effective through robust clinical trials". These early results covering trial volunteers from the United Kingdom in the 56-69 and 70+ age groups have been submitted to a peer-review journal, and we hope to see their publication in the coming weeks.
Oxford Covid vaccine prompts immune response among.
UK Health Secretary Matt Hancock further fuelled optimism Monday, noting in an interview that once approved the "bulk" of the vaccine's rollout could occur in Britain before next summer.
Speaking about the third phase, Dr E Venkata Rao, Principal Investigator in the Covaxin human trial and Professor in the Department of Community Medicine at IMS and SUM Hospital said that the indigenous vaccine, being developed by ICMR and Bharat Biotech, has received the approval of the Central Drugs Standard Control Organisation (CDSCO) for initiating the third phase trial as reported by ANI.
There has also been developments in the United States regarding a vaccine breakthrough.
AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world as it gets closer to reporting early results of a late-stage clinical trial.